Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study
Irene Santos-Pardo, Nils Witt, Oskar Angerås, Thomas Nyström · 2023
Read Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study by Irene Santos-Pardo, Nils Witt, Oskar Angerås, Thomas Nyström (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10709975.txt.
Description
Santos-Pardo and co-authors present a 2023 trial on whether a diabetes drug helps heart stents heal. People with type 2 diabetes face higher odds of stent clogging and clots. The drug exenatide, a gut-hormone mimic, may calm vessel walls. Thirty-eight patients getting a modern drug-coated stent joined the Rebuild study, half adding weekly exenatide to standard care.
After twelve weeks, a new vessel scan measured how much of each stent strut had grown a cell cover. Coverage was high in both groups, near ninety-five and ninety-one percent. The gap was not significant, and new tissue thickness matched as well. The drug showed no clear healing edge in this small trial.
Catalog record
| CREATOR | Irene Santos-Pardo, Nils Witt, Oskar Angerås, Thomas Nyström |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |